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Abstract
Purpose Preclinical data indicate that the combination of
docetaxel, cisplatin and trastuzumab (TCH) may have the
potential for clinically signiWcant activity against breast
cancers that overexpress the her2/neu gene (HER2). An
open-label phase II trial was designed to investigate the
response rate and toxicity proWle of TCH in breast cancer
patients with a primary tumor 2–5 cm in diameter (T2) in
its original size.
Methods Thirty breast cancer patients with HER2-over-
expressing tumors were enrolled. Patients received 6 cycles
of docetaxel at 60 mg/m2 and cisplatin at 50 mg/m2 given
on day 1 and then every 21 days. Trastuzumab was given
on day 1, cycle 1 (4 mg/kg), and then continued weekly at
2 mg/kg for 1 year or until disease progression. Tumor
measurements were obtained at baseline as well as after 3
and 6 cycles of chemotherapy.
Results We identiWed 29 breast cancer patients in Taiwan,
of whom 13 (44.8%) had pathological complete responses.
No cardiac toxicity was observed. Hematologic grade 4 or
3 toxicities were observed in 1 of 28 patients. Non-hemato-
logic grade 4 or 3 toxicities with a reverse pattern were
observed in 6 of 29 patients.
Conclusions The results of our study indicate that TCH
neoadjuvant chemotherapy is feasible and active in T2
HER2-overexpressing breast cancer patients in terms of
pathological complete response rate, complete response,
partial response and manageable toxicities.
Keywords Breast cancer · HER2 · Docetaxel · Cisplatin · 
Trastuzumab
Introduction
Preclinical data indicate that the combination of docetaxel,
cisplatin and trastuzumab (TCH) may have the potential for
clinically signiWcant activity against breast cancers that
overexpress the her2/neu gene (HER2) [1–3]. The potential
advantage of neoadjuvant chemotherapy is in the ability to
assess the response rate in vivo and in downstaging the pri-
mary tumor and regional lymphatic metastases, which
improves the cosmetic result. Neoadjuvant chemotherapy
may also kill tumor cells before drug resistance develops.
Clinical and pathological responses may remain the most
important variables in predicting breast cancer outcome
after chemotherapy. Furthermore, patients experiencing a
pathologic complete response (pCR) have a statistically
signiWcant survival beneWt [1, 2]. Liedtke [1] reported that
triple-negative breast cancer with a pCR has excellent
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response rate (24%) for paclitaxel and cisplatin in patients
with locally advanced breast cancer and concluded that
adjuvant paclitaxel and cisplatin in a multidisciplinary
strategy were highly eVective [2].
Of interest, some recent studies have suggested that
there might be a signiWcantly higher pCR after trastuzumab
target therapy [3–6]. Pegram [3] showed that combinations
of docetaxel, a platinum salt, and trastuzumab are feasible
and active in patients with advanced breast cancers that
overexpress the her2/neu gene (HER2). Buzdar [4] reported
a higher pCR after neoadjuvant therapy with paclitaxel, epi-
rubicin and trastuzumab chemotherapy in human epidermal
growth factor receptor 2-positive operable breast cancer.
Robert [6] showed that the addition of carboplatin to paclit-
axel and trastuzumab improved the objective response rate
and progression-free survival in women with HER2-over-
expressing metastatic breast cancer. However, whether
TCH neoadjuvant chemotherapy is feasible remains an
open question. Information on TCH neoadjuvant chemo-
therapy is still confusing and limited [7–19].
Traditionally, breast carcinoma classiWcation using gene
expression proWles and IHC biomarkers has identiWed at
least 4 subtypes [20]. These subtypes are luminal A (estro-
gen receptor [ER]-positive and/or progesterone receptor
[PgR]-positive and HER2-negative), luminal B (ER-posi-
tive and/or PgR-positive and HER2-positive), basal-like
(ER-negative, PgR-negative and HER2-negative) and
HER2-positive (ER-negative, PgR-negative and HER2-
positive) [14–20]. In this study, luminal B and the so-called
HER2-positive subtypes were deWned as HER2-over-
expressing breast cancer. An open-label phase II trial was
designed to investigate the response rate and toxicity proWle
of TCH in HER2-overexpressing breast cancer patients
with a primary tumor 2–5 cm in diameter (T2) in its origi-
nal size.
Materials and methods
Patients
Patients were enrolled from National Taiwan University
Hospital (Taipei, Taiwan), China Medical University Hos-
pital (Taichung, Taiwan), National Cheng Kung University
Hospital (Tainan, Taiwan) and Changhua Christian Hospi-
tal (Changhua, Taiwan) aggregately, between January 2007
and July 2009. The inclusion criteria were as follows: (1)
women aged 18 years or older, cooperative patients with
informed consent and histologically conWrmed invasive
ductal breast cancer (T2, N0-N1, M0) with needle core
biopsy; (2) HER2 overexpression detected by Xuorescence
in situ hybridization (FISH) + or immunohistochemistry
(IHC) 3+, and measurable disease; (3) Eastern Cooperative
Oncology Group (ECOG) performance status 0 or 1; (4)
white cell count of at least 4,000 cells/l and platelet count
of at least 100,000 cells/l; total bilirubin level within the
institutional normal range; aspartate transaminase of not
greater than 2 times the upper limit of normal; serum creat-
inine levels less than 1.5 mg/dl; and (5) left ventricular
ejection fraction of at least 50%. The exclusion criteria
were as follows:(1) distant metastases; (2) previous chemo-
therapy for breast cancer; (3) prior malignancy not treated
with curative intent; (4) synchronous breast cancer; (5)
pregnancy or nursing; (6) uncontrolled infection, active car-
diovascular or pulmonary disease, uncontrolled diabetes
mellitus or peripheral neuropathy of any etiology exceeding
grade 1; and (7) hepatitis B or hepatitis C carriers. The pri-
mary endpoint of this phase II trial was the objective
response rate for the regimen. The secondary endpoints
included treatment-related toxicity. Estimated time for
patient accrual was 3 months. All the patients received at
least 3 courses of TCH therapy. This study was approved
by the institutional review board of Changhua Christian
Hospital. All patients enrolled on this study gave the writ-
ten informed consent to take part in the trial.
Study design
The baseline data were based on the availability of demo-
graphic characteristics (e.g., age) and tumor characteristics
(e.g., tumor size, ER/PgR/HER2 information and histol-
ogy).
Tumor size was determined based on pathological
reports from National Taiwan University Hospital, China
Medical University Hospital, National Cheng Kung Uni-
versity Hospital and Changhua Christian Hospital. Staging
in this study was in accordance with the American Joint
Committee on Cancer staging group guidelines. ER and
PgR statuses were assessed by IHC, which was performed
with anti-ER (NeoMarkers, SP1 clone, dilution: 1:200, Fre-
mont, California) and anti-PgR antibody (NeoMarkers, SP2
clone, dilution: 1:250, Fremont, California) using an auto-
staining system (Ventana Medical Systems, Tucson, Ari-
zona). IHC analysis was carried out on all preneoadjuvant
and most of the post-neoadjuvant chemotherapy-treated
specimens. IHC was performed on paraYn-embedded and
formalin-Wxed breast cancer tissue; 10% or greater of cells
with nuclear staining for ER and PgR, respectively, was
considered a positive result. HER2 overexpression was
deWned as being scored as either 3+ (IHC) or HER2 gene
ampliWcation (FISH). HER2 overexpression on each tumor
was assessed according to the current 2007 CAP/ASCO
guideline scoring system.
All treatments were given intravenously. In the Wrst cycle,
a trastuzumab loading dose (4 mg/kg) was given for over123
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intravenously for 60 min on day 1, followed by cisplatin at a
50 mg/m2 infusion intravenously for 24 h. Trastuzumab at
2 mg/kg was subsequently given for 30 min on days 8 and
15. In the remaining cycles, docetaxel and cisplatin were
infused on day 1 immediately following trastuzumab.
Prophylactic steroid consisted of dexamethasone at 8 mg
administered orally the night before docetaxel infusion, the
morning of the infusion, 1 h before docetaxel and twice daily
for 36 h thereafter. All patients received intravenous hydra-
tion with at least 1 l of normal saline before and after receiv-
ing cisplatin. Treatment continued for 6 cycles unless there
was unacceptable toxicity or disease progression. Trast-
uzumab was continued weekly at 2 mg/kg for 1 year after
chemotherapy ended. For all toxicities, treatment was discon-
tinued until recovery to grade 1. After recovery, treatment
was resumed in subsequent cycles. Treatment after recur-
rence was based on the St. Gallen or NCCN guidelines and
multidisciplinary discussions. The patients with recurrence
underwent adjuvant systemic chemotherapy.
Patients with invasive breast carcinoma, whose needle
core biopsy and subsequent excision biopsy specimens
(lumpectomy or mastectomy) were pathologically evalu-
ated, were identiWed. “No change” was deWned as no sig-
niWcant diVerence found in the same patient between pre-
and post-neoadjuvant chemotherapy. Tumor response was
classiWed according to World Health Organization criteria.
Response was assessed and reported by the investigators.
Toxicity was graded according to the National Cancer Insti-
tute Common Toxicity Criteria (version 3.0).
Statistics
Statistical analyses were performed using PASW 18 soft-
ware (SPSS, Inc., Chicago, IL). We expressed data as
mean § standard deviation for continuous variables. Inde-
pendent t tests were used for the comparison of continuous
variables, and categorical variables were normally tested
with the 2 test when appropriate. All P values were two-
tailed; a P value of less than 0.05 was considered to indi-
cate statistical signiWcance. A Simon two-stage optimal
design was used for deWnition of the total number of
patients required for this phase II trial. The study was
designed to have 80% power to accept the hypothesis and
5% signiWcance to reject the hypothesis.
Ethical aspects
The study was conducted in accordance with the Declara-
tion of Helsinki and approved by the Institutional Review
Boards of the participating institutions. All patients pro-
vided their written informed consents prior to the study
enrollment.
Results
We enrolled 30 breast cancer patients with HER2-over-
expressing tumors and excluded one due to lack of avail-
ability of data. The study group included 29 assessable
women with an average age of 52 years (standard deviation
5.66 years, Table 1). All patients had HER2 overexpression
documented by IHC (2+ or 3+) or evidence of HER2 gene
ampliWcation by FISH. Twenty-eight (96%) of 29 patients
in this trial had an IHC score of 3+ or positive by FISH at
the time of initial screening for study entry. Ninety-six per-
cent of patients received 6 courses of TCH chemotherapy.
Thirteen patients (44.8%) had pCR, 9 (31.0%) had a com-
plete response, 13 (44.8%) had a partial response, 2 (6.9%)
had stable disease, and 1 (3.4%) had progressive disease
(Table 2). In this study, pCR was deWned as pathological
complete response without residual invasive disease.
Therefore, we included one patient with residual ductal car-
cinoma in situ following neoadjuvant chemotherapy in the
Table 1 Descriptive statistics of patients
SD standard deviation, ER estrogen receptor, PgR progesterone
receptor
*** A P value <0.0001
a The statuses of hormone receptors and HER2 were determined on
primary tumor tissue
Features Total
Age, years (SD) 52 (5.66)
Tumor size, cm (SD)***
Before TCH 2.885 (0.83)
After TCH 1.3 (1.70)
ERa status
Negative 18
Positive 11
PgRa status
Negative 20
Positive 9
Subgroup
ER+ and/or PgR+ and HER2+a 11
ER¡, PgR¡ and HER2+a 18
Menopausal status
Premenopause 17
Postmenopause 12
Extent of surgery
Total mastectomy 20
Partial mastectomy 9
Histological positive nodes after TCH
Positive 3
Negative 26123
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involvement after neoadjuvant chemotherapy in the pCR
group.
No cardiac toxicity was observed (Table 3). Hemato-
logic grades 4 or 3 toxicities were observed in 1 of 28
patients, and grades 2 or 1 toxicities were observed in 18 of
28 patients. Non-hematologic grades 4 or 3 toxicities were
observed in 6 of 29 patients, and grades 2 or 1 were
observed in 20 of 29 patients. For all toxicities, treatment
was discontinued until recovery to grade 1. After recovery,
treatment was resumed in subsequent cycles. All patients
recovered within a short time. In 1 patient with severe
hematologic toxicity, docetaxel doses were modiWed to
45 mg/m2. Overall, the TCH regimen was well tolerated,
with manageable toxicities.
One patient had brain metastasis, received whole brain
radiotherapy and then died of breast cancer in May 2010.
Another patient had lung metastasis and local recurrence
and was alive at the latest follow-up in July 2010.
The data on biomarker changes showed that ER status
remained unchanged in the majority of cases, 58.6%, when
comparing preneoadjuvant and post-neoadjuvant chemo-
therapy-treated specimens (Table 4); 41% of PgR status,
34.5% of HER2 IHC status and 60.0% of HER2 FISH sta-
tus remained unchanged.
The analyses of ER subgroups, ER-positive versus ER-
negative, revealed that there was no statistically signiWcant
diVerence in pCR, in addition to partial response, stable dis-
ease and progressive disease, between ER subgroups
(Table 5).
Discussion
The use of the TCH combination had the following ratio-
nales: First, each component has good activity against
breast cancer. Second, the major toxicities of each compo-
nent in this novel regimen are generally non-overlapping.
Finally, the synergistic reactions of these active agents have
been well established. We hypothesized that this regimen
should have high clinical and pathological response rates
with acceptable and manageable toxicities.
In this study, we reported 0% cardiac toxicity. Our Wnd-
ings supported those from other studies in terms of cardiac
toxicity. In the study by Buzdar et al. [4], they investigated
the eVects of trastuzumab addition on neoadjuvant chemo-
therapy in operable breast cancer patients with HER2-over-
expressing disease and found that none of these patients
developed clinical congestive heart failure (95% CI, 0% to
14.8%). A greater than 10% decrease in the left ventricle
ejection fraction was observed in Wve and seven patients in
the chemotherapy alone and trastuzumab plus chemother-
apy arms, respectively, when trastuzumab was adminis-
tered concurrently with paclitaxel and epirubicin, a possibly
toxic combination for the heart [4]. Gianni reported that the
NOAH trial results that revealed only 2 patients (2%)
developed symptomatic cardiac failure and both responded
to cardiac drugs. Our data contrasted with those of the
series of Slamon et al. [14] in which 13% of 92 patients
with paclitaxel plus trastuzumab developed heart failure;
the race factor and the sample size factor could have con-
tributed to the diVerence.
Table 2 Descriptive statistics of patients, clinical and pathological
responses
Features Total (%)
Pathological complete response 13 (44.8)
Complete response 9 (31.0)
Partial response 13 (44.8)
Stable disease 2 (6.9)
Progressive disease 1 (3.4)
Table 3 Descriptive statistics of patients, toxicity
Cumulative incidence, all chemotherapy cycles
Features Total (%)
Cardiac toxicity (n = 28)
Cardiac death 0 (0)
Ventricular arrhythmia 0 (0)
Cardiac hypotension 0 (0)
Hematologic grade 4 or 3 toxicities
Neutropenia (n = 28) 0 (0.0)
Leukopenia (n = 28) 0 (0.0)
Anemia (n = 27) 1 (3.7)
Thrombocytopenia (n = 28) 0 (0)
Hematologic grade 2 or 1 toxicities
Neutropenia (n = 28) 1 (3.5)
Leukopenia (n = 28) 1 (3.6)
Anemia (n = 27) 18 (66.7)
Thrombocytopenia (n = 27) 1 (3.7)
Non-hematologic grade 4 or 3 toxicity (n = 28)
Diarrhea 2 (7.1)
Nausea/Vomiting 4 (14.3)
Alopecia 2 (7.1)
Skin rash 0 (0)
Hypersensitivity 1 (3.6)
Non-hematologic grade 2 or 1 toxicity (n = 28)
Diarrhea 12 (42.9)
Nausea/Vomiting 21 (75.0)
Alopecia 17 (60.7)
Skin rash 1 (3.6)
Hypersensitivity 0 (0)123
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overexpressed breast carcinoma have signiWcantly better
responses when treated with trastuzumab simultaneously
with neoadjuvant chemotherapy than with chemotherapy
alone. The inclusion of trastuzumab as part of a neoadjuvant
chemotherapy regimen yields a higher pCR rate and a
greater percentage of patients that are disease free than neo-
adjuvant chemotherapy alone [9, 21–23]. The increasing
number of patients with breast cancer being treated in the
TCH neoadjuvant setting gives rise to a need to assess bio-
markers accurately in the needle biopsy material, which is
usually the only available tissue before treatment. How-
ever, concordance rates between FISH-determined HER2
status on needle core biopsies and on subsequent excision
biopsies of the same tumor have not been well studied. Our
Wndings support the results of the D’Alfonso study [23] that
HER2 status remains unchanged in the majority of cases
when comparing preneoadjuvant and post-neoadjuvant che-
motherapy-treated specimens. D’Alfonso found that excel-
lent overall concordance was achieved between the FISH-
determined HER2 status in the needle core biopsy and that
determined in the subsequent excision biopsy of the same
tumor. D’Alfonso [23] also mentioned that there is a sur-
prising lack of published evidence showing the concor-
dance rate between the FISH-determined HER2 status of
the two types of biopsy specimens from the same tumor.
There are potential limitations to this study. In Taiwan,
trastuzumab-targeted therapy has been administered only to
metastatic breast cancer patients, up to August 2010, due to
this country’s national health insurance policy. Because of
cardiac toxicity and budget concerns, the use of trast-
uzumab outside of the national health insurance system up
to 2006 was rare among Taiwanese women with HER2-
overexpressing breast cancer, which may have contributed
to our dropout rate. One patient in this trial dropped out
after only 3 courses of TCH neoadjuvant chemotherapy.
Time is needed for patients to accept this costly drug.
Cameron et al. [24] showed the observation that patients
whose tumors achieve a pathologic pCR to presurgical
treatment have a better outcome gave many hope that it
could be a validated surrogate for disease-free, if not over-
all, survival. Untch et al. [25] reported that pCR was the
only signiWcant prognostic factor for three-year disease-
free survival (hazard ratio 2.5; 95% conWdence interval,
1.2–5.1; P = 0.013) in multivariate analysis when breast
cancer patients with pCR compared to patients without
pCR after neoadjuvant chemotherapy plus trastuzumab.
This study is the Wrst Taiwanese phase II trial on eligibility
and toxicity of TCH neoadjuvant chemotherapy. It indicates
that T2 breast cancer patients with HER2-overexpressing
tumors are eligible for TCH neoadjuvant chemotherapy in
terms of pCR, complete response and partial response rates,
and manageable toxicities.
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Table 4 Biomarker changes in women with T2 breast cancer given
TCH neoadjuvant chemotherapy
ER estrogen receptor, PgR progesterone receptor
Biomarker Total, n (%)
ER status (n = 29)
3 + to 2+ 1 (3.4)
2 + to x 1 (3.4)
+ to x 2 (6.9)
¡ to x 8 (27.6)
No change (%) 17 (58.6)
PgR status (n = 29)
3 + to ¡ 1 (3.4)
+ to 2+ 1 (3.4)
+ to ¡ 2 (6.9)
+ to x 2 (6.9)
¡ to x 9 (31.0)
¡ to + 2 (6.9)
No change (%) 12 (41.4)
HER2 status by immunohistochemistry (n = 29)
3+ to 2+ 3 (10.3)
3+ to + 3 (10.3)
3+ to ¡ 3 (10.3)
3+ to x 10 (34.5)
No change (%) 10 (34.5)
HER2 status by Xuorescence in situ 
hybridization (n = 25)
+ to ¡ 2 (8.0)
+ to x 7 (28.0)
¡ to + 1 (4.0)
No change (%) 15 (60.0)
Table 5 Data on ER-positive versus ER-negative subgroups of wom-
en with T2 HER2-overexpressing breast cancer given TCH neoadju-
vant chemotherapy
ER estrogen receptor, PgR progesterone receptor
a The P values were calculated by Fisher’s exact test
ER-positive 
(n = 11)
ER-negative 
(n = 18)
Pa
Pathological 
complete response (%)
3 (27.3) 10 (55.6) >0.05
Complete response (%) 3 (27.3) 6 (33.3) >0.05
Partial response (%) 8 (72.7) 5 (27.8) >0.05
Stable disease (%) 0 2 (11.1) >0.05
Progressive disease (%) 0 1 (5.6) >0.05123
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